B Cell Lymphocytosis in Juvenile Dermatomyositis
In this study, we determined if B lymphocytosis may serve as a JDM biomarker for disease activity. Children with untreated JDM were divided into two groups based on age-adjusted B cell percentage (determined through flow cytometry): 90 JDM in the normal B cell group and 45 in the high B cell group....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/16/2626 |
| _version_ | 1797585021284909056 |
|---|---|
| author | Christopher Costin Amer Khojah Elisa Ochfeld Gabrielle Morgan Saravanan Subramanian Marisa Klein-Gitelman Xiao-Di Tan Lauren M. Pachman |
| author_facet | Christopher Costin Amer Khojah Elisa Ochfeld Gabrielle Morgan Saravanan Subramanian Marisa Klein-Gitelman Xiao-Di Tan Lauren M. Pachman |
| author_sort | Christopher Costin |
| collection | DOAJ |
| description | In this study, we determined if B lymphocytosis may serve as a JDM biomarker for disease activity. Children with untreated JDM were divided into two groups based on age-adjusted B cell percentage (determined through flow cytometry): 90 JDM in the normal B cell group and 45 in the high B cell group. We compared through <i>T</i>-testing the age, sex, ethnicity, duration of untreated disease (DUD), disease activity scores for skin (sDAS), muscle (mDAS), total (tDAS), CMAS, and neopterin between these two groups. The patients in the high B cell group had a higher tDAS (<i>p</i> = 0.009), mDAS (<i>p</i> = 0.021), and neopterin (<i>p</i> = 0.0365). Secondary analyses included B cell values over time and BAFF levels in matched patients with JM (juvenile myositis) and concurrent interstitial lung disease (ILD); JM alone and healthy controls Patient B cell percentage and number was significantly higher after 3–6 months of therapy and then significantly lower on completion of therapy (<i>p</i> =< 0.0001). The JM groups had higher BAFF levels than controls 1304 vs. 692 ng/mL (<i>p</i> = 0.0124). This study supports B cell lymphocytosis as a JDM disease-activity biomarker and bolsters the basis for B cell-directed therapies in JDM. |
| first_indexed | 2024-03-10T23:59:50Z |
| format | Article |
| id | doaj.art-05f7d852d0f147e1974bf71a08c40f5c |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T23:59:50Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-05f7d852d0f147e1974bf71a08c40f5c2023-11-19T00:47:48ZengMDPI AGDiagnostics2075-44182023-08-011316262610.3390/diagnostics13162626B Cell Lymphocytosis in Juvenile DermatomyositisChristopher Costin0Amer Khojah1Elisa Ochfeld2Gabrielle Morgan3Saravanan Subramanian4Marisa Klein-Gitelman5Xiao-Di Tan6Lauren M. Pachman7Division of Pediatric Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USADepartment of Pediatrics, College of Medicine, Umm Al-Qura University, Makkah 24341-6660, Saudi ArabiaDivision of Allergy and Immunology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USADivision of Pediatric Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USADepartment of Pediatrics, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USADivision of Pediatric Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USADepartment of Pediatrics, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USADivision of Pediatric Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USAIn this study, we determined if B lymphocytosis may serve as a JDM biomarker for disease activity. Children with untreated JDM were divided into two groups based on age-adjusted B cell percentage (determined through flow cytometry): 90 JDM in the normal B cell group and 45 in the high B cell group. We compared through <i>T</i>-testing the age, sex, ethnicity, duration of untreated disease (DUD), disease activity scores for skin (sDAS), muscle (mDAS), total (tDAS), CMAS, and neopterin between these two groups. The patients in the high B cell group had a higher tDAS (<i>p</i> = 0.009), mDAS (<i>p</i> = 0.021), and neopterin (<i>p</i> = 0.0365). Secondary analyses included B cell values over time and BAFF levels in matched patients with JM (juvenile myositis) and concurrent interstitial lung disease (ILD); JM alone and healthy controls Patient B cell percentage and number was significantly higher after 3–6 months of therapy and then significantly lower on completion of therapy (<i>p</i> =< 0.0001). The JM groups had higher BAFF levels than controls 1304 vs. 692 ng/mL (<i>p</i> = 0.0124). This study supports B cell lymphocytosis as a JDM disease-activity biomarker and bolsters the basis for B cell-directed therapies in JDM.https://www.mdpi.com/2075-4418/13/16/2626B cellBAFFneopterinjuvenile dermatomyositisT cellbiomarkers |
| spellingShingle | Christopher Costin Amer Khojah Elisa Ochfeld Gabrielle Morgan Saravanan Subramanian Marisa Klein-Gitelman Xiao-Di Tan Lauren M. Pachman B Cell Lymphocytosis in Juvenile Dermatomyositis Diagnostics B cell BAFF neopterin juvenile dermatomyositis T cell biomarkers |
| title | B Cell Lymphocytosis in Juvenile Dermatomyositis |
| title_full | B Cell Lymphocytosis in Juvenile Dermatomyositis |
| title_fullStr | B Cell Lymphocytosis in Juvenile Dermatomyositis |
| title_full_unstemmed | B Cell Lymphocytosis in Juvenile Dermatomyositis |
| title_short | B Cell Lymphocytosis in Juvenile Dermatomyositis |
| title_sort | b cell lymphocytosis in juvenile dermatomyositis |
| topic | B cell BAFF neopterin juvenile dermatomyositis T cell biomarkers |
| url | https://www.mdpi.com/2075-4418/13/16/2626 |
| work_keys_str_mv | AT christophercostin bcelllymphocytosisinjuveniledermatomyositis AT amerkhojah bcelllymphocytosisinjuveniledermatomyositis AT elisaochfeld bcelllymphocytosisinjuveniledermatomyositis AT gabriellemorgan bcelllymphocytosisinjuveniledermatomyositis AT saravanansubramanian bcelllymphocytosisinjuveniledermatomyositis AT marisakleingitelman bcelllymphocytosisinjuveniledermatomyositis AT xiaoditan bcelllymphocytosisinjuveniledermatomyositis AT laurenmpachman bcelllymphocytosisinjuveniledermatomyositis |